Haemonetics Historical Balance Sheet

HAE Stock

USD 87.89 0.64 0.72%

Trend analysis of Haemonetics balance sheet accounts such as Short and Long Term Debt Total of 848.2 M or Other Current Liab of 194.8 M provides information on Haemonetics' total assets, liabilities, and equity, which is the actual value of Haemonetics to its prevalent stockholders. By breaking down trends over time using Haemonetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Haemonetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Haemonetics is a good buy for the upcoming year.

Haemonetics Inventory

333.06 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

About Haemonetics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Haemonetics at a specified time, usually calculated after every quarter, six months, or one year. Haemonetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Haemonetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Haemonetics currently owns. An asset can also be divided into two categories, current and non-current.

Haemonetics Balance Sheet Chart

At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 194.8 M, whereas Total Current Liabilities is forecasted to decline to about 161.5 M.

Common Stock Shares Outstanding Total Assets Short Long Term Debt Total Other Current Liab

Add Fundamental

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Assets

Total assets refers to the total amount of Haemonetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Haemonetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most accounts from Haemonetics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 194.8 M, whereas Total Current Liabilities is forecasted to decline to about 161.5 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	773.6M	765.9M	807.8M	848.2M
Total Assets	1.9B	1.9B	2.2B	2.3B

Short Long Term Debt Total Total Assets

Haemonetics balance sheet Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Short Term Investments
Common Stock Shares Outstanding		-0.68	-0.59	-0.69	0.02	-0.11	0.01	-0.57	-0.19	-0.6	-0.14	-0.68	0.06	-0.15	-0.09	-0.62	-0.63	-0.13	-0.59	-0.62	-0.61	-0.13	0.16	-0.66	-0.02	0.34
Total Assets	-0.68		0.94	0.82	0.5	0.64	0.48	0.87	0.3	0.91	0.58	0.99	0.07	0.59	0.6	0.92	0.93	0.58	0.89	0.96	0.81	0.74	0.05	0.95	0.59	-0.57
Short Long Term Debt Total	-0.59	0.94		0.68	0.47	0.44	0.35	0.97	0.07	0.79	0.46	0.95	-0.02	0.46	0.45	0.97	0.91	0.59	0.8	0.99	0.83	0.66	0.07	0.92	0.59	-0.33
Other Current Liab	-0.69	0.82	0.68		0.38	0.47	0.28	0.59	0.16	0.86	0.53	0.78	-0.14	0.53	0.51	0.71	0.8	0.3	0.83	0.76	0.75	0.59	-0.08	0.7	0.24	-0.47
Total Current Liabilities	0.02	0.5	0.47	0.38		0.54	0.57	0.38	-0.07	0.56	0.59	0.45	-0.21	0.59	0.59	0.3	0.54	0.43	0.65	0.5	0.44	0.7	0.8	0.36	0.65	-0.49
Total Stockholder Equity	-0.11	0.64	0.44	0.47	0.54		0.79	0.3	0.67	0.61	0.75	0.58	0.34	0.74	0.87	0.41	0.49	0.55	0.59	0.46	0.34	0.87	0.12	0.54	0.63	-0.85
Property Plant And Equipment Net	0.01	0.48	0.35	0.28	0.57	0.79		0.29	0.36	0.58	0.41	0.46	0.04	0.41	0.86	0.27	0.38	0.12	0.59	0.35	0.31	0.65	0.22	0.31	0.85	-0.71
Net Debt	-0.57	0.87	0.97	0.59	0.38	0.3	0.29		-0.02	0.71	0.25	0.91	-0.07	0.25	0.34	0.96	0.87	0.51	0.73	0.95	0.78	0.51	0.01	0.89	0.6	-0.18
Retained Earnings	-0.19	0.3	0.07	0.16	-0.07	0.67	0.36	-0.02		0.23	0.36	0.29	0.69	0.36	0.41	0.1	0.01	0.27	0.03	0.06	0.09	0.3	-0.19	0.34	0.11	-0.54
Accounts Payable	-0.6	0.91	0.79	0.86	0.56	0.61	0.58	0.71	0.23		0.57	0.87	0.01	0.57	0.71	0.76	0.82	0.35	0.9	0.84	0.78	0.7	0.11	0.76	0.6	-0.6
Cash	-0.14	0.58	0.46	0.53	0.59	0.75	0.41	0.25	0.36	0.57		0.48	0.18	1.0	0.65	0.41	0.48	0.58	0.56	0.49	0.46	0.86	0.26	0.43	0.28	-0.67
Non Current Assets Total	-0.68	0.99	0.95	0.78	0.45	0.58	0.46	0.91	0.29	0.87	0.48		0.05	0.49	0.54	0.94	0.91	0.55	0.85	0.96	0.82	0.67	0.02	0.97	0.6	-0.49
Non Currrent Assets Other	0.06	0.07	-0.02	-0.14	-0.21	0.34	0.04	-0.07	0.69	0.01	0.18	0.05		0.17	0.15	0.02	-0.08	0.34	-0.24	-0.05	-0.22	0.16	-0.24	0.17	0.05	-0.23
Cash And Short Term Investments	-0.15	0.59	0.46	0.53	0.59	0.74	0.41	0.25	0.36	0.57	1.0	0.49	0.17		0.65	0.41	0.48	0.58	0.56	0.49	0.46	0.86	0.26	0.44	0.28	-0.67
Net Receivables	-0.09	0.6	0.45	0.51	0.59	0.87	0.86	0.34	0.41	0.71	0.65	0.54	0.15	0.65		0.41	0.52	0.31	0.66	0.48	0.42	0.85	0.13	0.42	0.71	-0.78
Non Current Liabilities Total	-0.62	0.92	0.97	0.71	0.3	0.41	0.27	0.96	0.1	0.76	0.41	0.94	0.02	0.41	0.41		0.9	0.57	0.76	0.97	0.79	0.61	-0.16	0.92	0.5	-0.28
Inventory	-0.63	0.93	0.91	0.8	0.54	0.49	0.38	0.87	0.01	0.82	0.48	0.91	-0.08	0.48	0.52	0.9		0.59	0.92	0.95	0.71	0.72	0.1	0.87	0.59	-0.49
Other Current Assets	-0.13	0.58	0.59	0.3	0.43	0.55	0.12	0.51	0.27	0.35	0.58	0.55	0.34	0.58	0.31	0.57	0.59		0.4	0.58	0.23	0.69	0.15	0.69	0.35	-0.36
Other Stockholder Equity	-0.59	0.89	0.8	0.83	0.65	0.59	0.59	0.73	0.03	0.9	0.56	0.85	-0.24	0.56	0.66	0.76	0.92	0.4		0.85	0.71	0.74	0.2	0.73	0.65	-0.65
Total Liab	-0.62	0.96	0.99	0.76	0.5	0.46	0.35	0.95	0.06	0.84	0.49	0.96	-0.05	0.49	0.48	0.97	0.95	0.58	0.85		0.83	0.68	0.06	0.93	0.58	-0.37
Property Plant And Equipment Gross	-0.61	0.81	0.83	0.75	0.44	0.34	0.31	0.78	0.09	0.78	0.46	0.82	-0.22	0.46	0.42	0.79	0.71	0.23	0.71	0.83		0.5	0.12	0.71	0.36	-0.22
Total Current Assets	-0.13	0.74	0.66	0.59	0.7	0.87	0.65	0.51	0.3	0.7	0.86	0.67	0.16	0.86	0.85	0.61	0.72	0.69	0.74	0.68	0.5		0.21	0.61	0.65	-0.72
Short Term Debt	0.16	0.05	0.07	-0.08	0.8	0.12	0.22	0.01	-0.19	0.11	0.26	0.02	-0.24	0.26	0.13	-0.16	0.1	0.15	0.2	0.06	0.12	0.21		-0.03	0.31	-0.2
Intangible Assets	-0.66	0.95	0.92	0.7	0.36	0.54	0.31	0.89	0.34	0.76	0.43	0.97	0.17	0.44	0.42	0.92	0.87	0.69	0.73	0.93	0.71	0.61	-0.03		0.51	-0.42
Common Stock Total Equity	-0.02	0.59	0.59	0.24	0.65	0.63	0.85	0.6	0.11	0.6	0.28	0.6	0.05	0.28	0.71	0.5	0.59	0.35	0.65	0.58	0.36	0.65	0.31	0.51		-0.51
Short Term Investments	0.34	-0.57	-0.33	-0.47	-0.49	-0.85	-0.71	-0.18	-0.54	-0.6	-0.67	-0.49	-0.23	-0.67	-0.78	-0.28	-0.49	-0.36	-0.65	-0.37	-0.22	-0.72	-0.2	-0.42	-0.51

Click cells to compare fundamentals

Haemonetics Account Relationship Matchups

Haemonetics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	51.8M	51.3M	51.4M	51.4M	51.4M	42.5M
Total Assets	1.3B	1.8B	1.9B	1.9B	2.2B	2.3B
Short Long Term Debt Total	382.5M	707.6M	773.6M	765.9M	807.8M	848.2M
Other Current Liab	127.7M	128.5M	116.8M	145.9M	185.6M	194.8M
Total Current Liabilities	284.3M	253.5M	442.3M	251.8M	300.4M	161.5M
Total Stockholder Equity	587.1M	731.7M	749.4M	818.0M	960.0M	535.9M
Property Plant And Equipment Net	253.4M	217.6M	258.5M	310.9M	366.6M	185.9M
Net Debt	245.2M	515.3M	514.1M	481.4M	629.0M	660.4M
Retained Earnings	78.5M	158.0M	202.4M	253.2M	360.5M	281.9M
Accounts Payable	50.7M	50.3M	58.4M	63.9M	73.4M	77.0M
Cash	137.3M	192.3M	259.5M	284.5M	178.8M	138.4M
Non Current Assets Total	663.5M	1.1B	1.1B	1.2B	1.4B	1.5B
Non Currrent Assets Other	66.3M	76.9M	63.2M	107.0M	81.1M	99.2M
Cash And Short Term Investments	137.3M	192.3M	259.5M	284.5M	178.8M	140.6M
Net Receivables	165.2M	127.6M	159.4M	179.1M	206.6M	120.7M
Liabilities And Stockholders Equity	1.3B	1.8B	1.9B	1.9B	2.2B	2.3B
Non Current Liabilities Total	395.7M	834.8M	668.0M	865.0M	935.2M	982.0M
Inventory	270.3M	322.6M	293.0M	259.4M	317.2M	333.1M
Other Current Assets	30.8M	102.1M	88.3M	46.7M	66.3M	40.1M
Other Stockholder Equity	553.2M	602.7M	572.5M	594.7M	634.6M	666.4M
Total Liab	680.0M	1.1B	1.1B	1.1B	1.2B	1.3B
Property Plant And Equipment Gross	305.6M	217.6M	869.1M	944.2M	959.2M	1.0B
Total Current Assets	603.6M	693.5M	756.0M	769.7M	768.9M	437.2M
Accumulated Other Comprehensive Income	(45.1M)	(29.5M)	(26.0M)	(30.4M)	(35.6M)	(37.4M)
Short Term Debt	77.0M	24.7M	221.3M	11.8M	10.2M	9.7M
Intangible Assets	133.1M	365.5M	310.3M	275.8M	406.1M	426.4M
Other Liab	48.7M	38.2M	76.9M	108.6M	124.9M	131.1M
Other Assets	14.1M	17.0M	67.7M	58.8M	1.0	0.95
Long Term Debt	305.5M	690.6M	559.4M	754.1M	797.6M	837.4M
Good Will	210.7M	466.4M	467.3M	466.2M	565.1M	593.3M
Property Plant Equipment	253.4M	277.4M	258.5M	310.9M	357.5M	213.6M
Current Deferred Revenue	28.8M	26.3M	31.8M	30.2M	31.2M	22.5M
Net Tangible Assets	243.4M	(100.3M)	(28.1M)	76.0M	68.4M	65.0M
Retained Earnings Total Equity	78.5M	158.0M	202.4M	253.2M	227.9M	230.9M
Long Term Debt Total	305.5M	690.6M	559.4M	754.1M	867.2M	910.6M
Capital Surpluse	553.2M	602.7M	572.5M	594.7M	683.9M	516.6M
Deferred Long Term Liab	10.6M	43.8M	28.7M	36.2M	41.6M	26.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics

Details

Is Haemonetics Stock a good investment?

Details

What is Haemonetics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.375

Earnings Share

2.41

Revenue Per Share

26.77

Quarterly Revenue Growth

0.086

Return On Assets

0.0588

The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Haemonetics Historical Balance Sheet

Haemonetics Inventory

333.06 Million

About Haemonetics Balance Sheet Analysis

Haemonetics Balance Sheet Chart

Common Stock Shares Outstanding

Total Assets

Haemonetics balance sheet Correlations

Haemonetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Haemonetics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Short Long Term Debt Total
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Liabilities Total	+ 0.97	Short Long Term Debt Total
Intangible Assets	+ 0.97	Non Current Assets Total

Short Term Investments	- 0.85	Total Stockholder Equity
Short Term Investments	- 0.78	Net Receivables
Short Term Investments	- 0.72	Total Current Assets
Short Term Investments	- 0.71	Property Plant And Equipment Net
Other Current Liab	- 0.69	Common Stock Shares Outstanding
Non Current Assets Total	- 0.68	Common Stock Shares Outstanding